50% off Premium Yearly

NYSE:IBM
This summary was created by AI, based on 22 opinions in the last 12 months.
IBM has positioned itself as a significant player in AI and quantum computing, with a diverse business portfolio that spans hybrid cloud and consulting services. Analysts note that despite some recent execution issues, particularly in the April earnings report, the company shows a positive trajectory, buoyed by substantial demand in data centers and a growing backlog. Many experts view current price levels as attractive entry points, suggesting buying opportunities around certain thresholds. However, there are mixed views about its valuation, with some experts believing it is overvalued after a robust rise due to AI hype. Overall, IBM's strategic focus on high-growth areas remains a point of confidence for many analysts, yet caution is advised regarding competition and market conditions.
Growing from multiple angles, yet valuation still reasonable. Stable and embedded business complemented by new growth drivers. Consulting business helps companies implement AI, and that's where the real spending is. Strong in hybrid cloud, managing data across environments. Quantum computing already being used with potential for energy, healthcare, manufacturing.
Drop in February due to sector rotation and profit taking. Trades ~19x PE, attractive. Sees 30% upside from here to ~$317. Yield is 2.85%.
Hold on to it. At 4-5% growth, in the ballpark of the top players. He doesn't know its exposure to robotics. Street's pretty positive on it, about 20% upside. At 20x PE, not an aggressive valuation. Margins expected to stay healthy -- 60% gross margins, net income margins of close to 20%.
(Analysts’ price target is $314.00)Has tripled since late 2022, and up 40% the past 12 months. They have terrific AI, cloud and consulting businesses. Also have quantum computing. Sales are up under a fine CEO. The rallied hard last October, but has pulled back. Its chart has double-bottomed and is rebounding like crazy. It's broken out of its 50-day moving average this week. Resistance is at $315, then the next at $335-345. There's more upside with the next leg higher coming. Momentum (MACD indicator) just made a bullish crossover, a positive signal. The On Balance Volume too. The RSI looks good, and can go higher. He liked their last quarter.
It has had quite a run with all the AI buzz. With it you have the same trade as you have with NVIDIA. It is a good business and will capture a solid portion of the software spend on AI. Ultimately though, how far away from commercialization is AI. The easy money has been made and IBM is over-valued at these levels.
Purchase of Red Hat really put them in the cloud and data centre business, saved them. Over last couple of years, execution of business plan was perfect. But more recently, especially in Q2 earnings, execution faltered. He's been adding in the $240 area. 12-month price target of $314.
IBM Common Stock is a American stock, trading under the symbol IBM (previously IBM-N on Stockchase) on the New York Stock Exchange (IBM). It is usually referred to as NYSE:IBM or IBM
In the last year, 23 stock analysts issued a Buy, Sell, or Hold rating on IBM (previously IBM-N on Stockchase). 16 analysts recommended to BUY and 6 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for IBM Common Stock.
IBM Common Stock was recommended as a Top Pick by Kim Bolton on 2025-09-10. Read the latest stock experts ratings for IBM Common Stock.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for IBM Common Stock.
IBM Common Stock is followed by 276 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-18, IBM Common Stock (IBM) stock closed at a price of $249.50.
Big into AI, huge into quantum. Checks all the boxes. Last earnings (April 22) were a bit of an execution slipup. He has a full position right now (4.5%). Buy here, add around $270, and again at $255. Yield is 2.43%.
(Analysts’ price target is $298.18)